Alnodesertib

N/A

Report date: 2026/03/19 20:00:18
NME

Base Information

Drug NameAlnodesertib
Drug Alias NameART-0380IACS-030380
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine-protein kinase ATR inhibitors
TargetsSerine-protein kinase ATR
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisEndometrial Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomFrance +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesShangPharma Innovation IncThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesArtios Pharma Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasm MetastasisEndometrial NeoplasmsFallopian Tube Neoplasms +[8] 
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A